title: Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months.
abstract: This study evaluates the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) in 115 children, aged 2-3 years (24-36 months), who have not been previously vaccinated with Prevenar.
  
  
  RESULTS
  
  
  
  RESULTS
  As for local reactions, 40% of children reported erythema, 32.2% induration and 39.1% tenderness at the injection site. Regarding systemic reactions, fever > or 38 C was recorded in 7% of patients. Other commonly reported events were decreased appetite (24.3%), restlessness (20%), and fussiness (18.3%).
  After vaccination, more than 98% of the subjects achieved antibody levels of > or = 0.15 microg/mL for all seven serotypes and more than 95% achieved antibody levels > or = 0.50 microg/mL for all serotypes.
  
  
  CONCLUSIONS
  Pneumococcal seven-valent conjugate vaccine (Prevenar) was safe, well tolerated and highly immunogenic when administered in previously unvaccinated children aged 14-36 months.
authors.affiliation: Pediatric Department, Basurto Hospital, Bilbao, Spain. aristegi@hbas.osakidetza.net
authors.forename: Javier
authors.initials: J
authors.lastname: de Arístegui Fernández
authors.forename: Begoña
authors.initials: B
authors.lastname: Cos Arregui
authors.forename: Ana
authors.initials: A
authors.lastname: Zurimendi Carril
authors.forename: Ma Victoria
authors.initials: MV
authors.lastname: Alday Esteban
authors.forename: Javier
authors.initials: J
authors.lastname: Alzua Ruiz
authors.forename: Emma
authors.initials: E
authors.lastname: De la Fuente Jausoro
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Maturana San Pedro
authors.forename: Ma José
authors.initials: MJ
authors.lastname: López Michelena
authors.forename: Carlos
authors.initials: C
authors.lastname: Mourelo Carballo
authors.forename: Maria Isabel
authors.initials: MI
authors.lastname: Quintanilla Sánchez
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Abad Therón
authors.forename: Carolyn O
authors.initials: CO
authors.lastname: Cimino
authors.forename: Mark A
authors.initials: MA
authors.lastname: Fletcher
authors.forename: Ana
authors.initials: A
authors.lastname: Pérez Domínguez
mesh_terms: D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D007223:Infant; D008297:Male; D011008:Pneumococcal Infections / Q000276:immunology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000009:adverse effects / Q000276:immunology*; D013030:Spain; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate